Reviews of Sanofi’s diabetes drug Tzield and Disc Medicine’s blood-disorder medicine bitopertin stalled Tzield pushed back after adverse event reports; bitopertin delayed two weeks amid efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results